Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fumihiro Fujiki

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
BMC Cancer|February 21, 2023
Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemiaHikaru Minagawa, Yoshiko Hashii, Hiroko Nakajima, et al.
Plos One|August 8, 2024
Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitorsMasaki Ito, Shigeo Koido, Takeo Iwamoto, et al.
Current Medicinal Chemistry|December 17, 2008
"Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further developmentYoshihiro Oka, Akihiro Tsuboi, Fumihiro Fujiki, et al.
Anti-Cancer Agents in Medicinal Chemistry|June 23, 2009
WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptideYoshihiro Oka, Akihiro Tsuboi, Fumihiro Fujiki, et al.
Diagnostics (Basel, Switzerland)|July 2, 2021
Imaging Assessment of Tumor Response in the Era of ImmunotherapyJun Nakata, Kayako Isohashi, Yoshihiro Oka, et al.
Thescientificworldjournal|July 11, 2007
WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancersYoshihiro Oka, Akihiro Tsuboi, Olga A Elisseeva, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 4, 2016
An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T CellsKenta Kondo, Fumihiro Fujiki, Hiroko Nakajima, et al.
Cancer Immunology, Immunotherapy : CII|July 23, 2020
Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptidesFumihiro Fujiki, Akihiro Tsuboi, Soyoko Morimoto, et al.
Cancer Immunology, Immunotherapy : CII|November 16, 2018
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant gliomaAkihiro Tsuboi, Naoya Hashimoto, Fumihiro Fujiki, et al.
International Journal of Hematology|March 15, 2006
WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignanciesZheyu Li, Yoshihiro Oka, Akihiro Tsuboi, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
BMC Cancer|February 21, 2023
Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemiaHikaru Minagawa, Yoshiko Hashii, Hiroko Nakajima, et al.
Plos One|August 8, 2024
Enhancing the immunogenicity of Wilms tumor 1 epitope in mesothelioma cells with immunoproteasome inhibitorsMasaki Ito, Shigeo Koido, Takeo Iwamoto, et al.
Current Medicinal Chemistry|December 17, 2008
"Cancer antigen WT1 protein-derived peptide"-based treatment of cancer -toward the further developmentYoshihiro Oka, Akihiro Tsuboi, Fumihiro Fujiki, et al.
Anti-Cancer Agents in Medicinal Chemistry|June 23, 2009
WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptideYoshihiro Oka, Akihiro Tsuboi, Fumihiro Fujiki, et al.
Diagnostics (Basel, Switzerland)|July 2, 2021
Imaging Assessment of Tumor Response in the Era of ImmunotherapyJun Nakata, Kayako Isohashi, Yoshihiro Oka, et al.
Thescientificworldjournal|July 11, 2007
WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancersYoshihiro Oka, Akihiro Tsuboi, Olga A Elisseeva, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 4, 2016
An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T CellsKenta Kondo, Fumihiro Fujiki, Hiroko Nakajima, et al.
Cancer Immunology, Immunotherapy : CII|July 23, 2020
Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptidesFumihiro Fujiki, Akihiro Tsuboi, Soyoko Morimoto, et al.
Cancer Immunology, Immunotherapy : CII|November 16, 2018
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant gliomaAkihiro Tsuboi, Naoya Hashimoto, Fumihiro Fujiki, et al.
International Journal of Hematology|March 15, 2006
WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A*0201-positive patients with hematopoietic malignanciesZheyu Li, Yoshihiro Oka, Akihiro Tsuboi, et al.
Pageof 6